12 Month Price Forecast For CDNA
Distance to CDNA Price Forecasts
CDNA Price Momentum
๐ค Considering CareDx (CDNA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 12:11 PM UTC
CDNA Analyst Ratings & Price Targets
Based on our analysis of 12 Wall Street analysts, CDNA has a bullish consensus with a median price target of $35.00 (ranging from $24.00 to $40.00). Currently trading at $24.50, the median forecast implies a 42.9% upside. This outlook is supported by 5 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sung Ji Nam at BTIG, projecting a 63.3% upside. Conversely, the most conservative target is provided by Brandon Couillard at Wells Fargo, suggesting a 2.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDNA Analyst Consensus
CDNA Price Target Range
Latest CDNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDNA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 15, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Upgrade | $24.00 |
Jan 14, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $26.00 |
Nov 5, 2024 | BTIG | Sung Ji Nam | Buy | Maintains | $35.00 |
Oct 22, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $0.00 |
Oct 16, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $35.00 |
Aug 27, 2024 | Wells Fargo | Brandon Couillard | Underweight | Initiates | $28.00 |
Aug 19, 2024 | BTIG | Sung Ji Nam | Buy | Upgrade | $40.00 |
Aug 1, 2024 | Craig-Hallum | Connor Chamberlain | Buy | Maintains | $32.00 |
Aug 1, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $0.00 |
Aug 1, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $26.00 |
Jul 17, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $16.00 |
May 31, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $0.00 |
May 17, 2024 | Craig-Hallum | Connor Chamberlain | Buy | Maintains | $22.00 |
May 15, 2024 | HC Wainwright & Co. | Yi Chen | Neutral | Reiterates | $0.00 |
May 13, 2024 | Raymond James | Andrew Cooper | Market Perform | Downgrade | $0.00 |
May 13, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $14.00 |
May 13, 2024 | Stephens & Co. | Mason Carrico | Overweight | Maintains | $18.00 |
May 9, 2024 | Craig-Hallum | Connor Chamberlain | Buy | Reiterates | $15.00 |
May 1, 2024 | Craig-Hallum | Alexander Nowak | Buy | Upgrade | $15.00 |
Apr 17, 2024 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $15.00 |
Stocks Similar to CareDx Inc
The following stocks are similar to CareDx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CareDx Inc (CDNA) Financial Data
CareDx Inc has a market capitalization of $1.31B with a P/E ratio of -6.9x. The company generates $312.78M in trailing twelve-month revenue with a -45.9% profit margin.
Revenue growth is +23.4% quarter-over-quarter, while maintaining an operating margin of -12.7% and return on equity of -43.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

CareDx Inc (CDNA) Company Overview
About CareDx Inc
Develops diagnostic solutions for transplant patients.
The company generates revenue by offering a range of diagnostic products and services specifically designed for transplant patients and their caregivers. This includes proprietary solutions like AlloSure and AlloMap, which utilize advanced technologies such as donor-derived cell-free DNA analysis and gene expression profiling. CareDx sells its products directly to customers and through third-party distributors, enhancing its market reach.
CareDx has established significant partnerships, including a license agreement with Illumina, Inc. for next-generation sequencing products. Additionally, the company provides a variety of software solutions for transplant management and patient care, indicating a comprehensive approach to supporting transplant recipients. Founded in 1998 and headquartered in South San Francisco, California, CareDx has a strong focus on innovation in the transplant diagnostics market.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
635
CEO
Mr. John Walter Hanna Jr.
Country
United States
IPO Year
2014
Website
caredx.comCareDx Inc (CDNA) Latest News & Analysis
CareDx, Inc. (Nasdaq: CDNA) will report its Q4 and full-year 2024 financial results on February 26, 2025, after market close, with a conference call at 1:30 PM PT.
CareDx's upcoming financial report could reveal key performance metrics and future outlook, influencing investor sentiment and stock price movements.
CareDx (CDNA) experienced significant trading volume recently, with trends in earnings estimate revisions potentially supporting further stock price increases.
Higher trading volume and positive earnings estimate revisions suggest increased investor interest and potential for further stock price appreciation in CareDx.
The Investment Committee has identified key stocks to monitor for the second half of the year.
The recommendation of top stocks signals potential growth opportunities, impacting investment strategies and portfolio adjustments for the second half of the year.
CareDx (CDNA) has a consensus price target suggesting a 42.3% upside potential, supported by an upward trend in earnings estimate revisions.
A 42.3% upside potential indicates significant growth potential for CareDx (CDNA), while rising earnings estimates suggest positive momentum, attracting investor interest.
New Strong Buy Stocks for January 30th
16 days agoOn January 30, 2024, BBCP, SDVKY, OBK, CDNA, and NVAX were added to the Zacks Rank #1 (Strong Buy) List.
Stocks on the Zacks Rank #1 list indicate strong potential for price appreciation, suggesting favorable investment opportunities for potential gains.
Best Momentum Stocks to Buy for January 30th
16 days agoOBK, BBCP, and CDNA are rated as Zacks Rank #1 (Strong Buy) momentum stocks as of January 30, 2024.
The inclusion of OBK, BBCP, and CDNA in the Zacks Rank #1 list signals strong growth potential, attracting investor interest and potentially driving stock prices higher.
Frequently Asked Questions About CDNA Stock
What is CareDx Inc's (CDNA) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, CareDx Inc (CDNA) has a median price target of $35.00. The highest price target is $40.00 and the lowest is $24.00.
Is CDNA stock a good investment in 2025?
According to current analyst ratings, CDNA has 5 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CDNA stock?
Wall Street analysts predict CDNA stock could reach $35.00 in the next 12 months. This represents a 42.9% increase from the current price of $24.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CareDx Inc's business model?
The company generates revenue by offering a range of diagnostic products and services specifically designed for transplant patients and their caregivers. This includes proprietary solutions like AlloSure and AlloMap, which utilize advanced technologies such as donor-derived cell-free DNA analysis and gene expression profiling. CareDx sells its products directly to customers and through third-party distributors, enhancing its market reach.
What is the highest forecasted price for CDNA CareDx Inc?
The highest price target for CDNA is $40.00 from Sung Ji Nam at BTIG, which represents a 63.3% increase from the current price of $24.50.
What is the lowest forecasted price for CDNA CareDx Inc?
The lowest price target for CDNA is $24.00 from Brandon Couillard at Wells Fargo, which represents a -2.0% decrease from the current price of $24.50.
What is the overall CDNA consensus from analysts for CareDx Inc?
The overall analyst consensus for CDNA is bullish. Out of 12 Wall Street analysts, 5 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are CDNA stock price projections?
Stock price projections, including those for CareDx Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.